Roivant Sciences Files 8-K
Ticker: ROIV · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1635088
Sentiment: neutral
Topics: sec-filing, regulation-fd, financial-reporting
TL;DR
Roivant filed a routine 8-K, no major news.
AI Summary
Roivant Sciences Ltd. filed an 8-K on September 9, 2024, to report on Regulation FD disclosures and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for the date.
Why It Matters
This filing indicates Roivant Sciences is meeting its public reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard current report and does not disclose any new material risks or events.
Key Players & Entities
- Roivant Sciences Ltd. (company) — Registrant
- September 9, 2024 (date) — Date of Report
FAQ
What is the purpose of this 8-K filing?
This 8-K filing is to report on Regulation FD disclosures and financial statements as of September 9, 2024.
What is the exact name of the company filing this report?
The exact name of the company is Roivant Sciences Ltd.
In which jurisdiction was Roivant Sciences Ltd. incorporated?
Roivant Sciences Ltd. was incorporated in Bermuda.
What is the principal executive office address of Roivant Sciences Ltd.?
The address of the Principal Executive Offices is 7th Floor 50 Broadway London SW1H 0DB United Kingdom.
Does this filing report any specific material events or financial results?
This filing primarily serves as a notification for Regulation FD disclosures and financial statements, and does not detail specific material events or financial results within the provided text.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-09-09 07:53:25
Key Financial Figures
- $0.0000000341740141 — nge on which registered Common Shares, $0.0000000341740141 per share ROIV The Nasdaq Global Se
Filing Documents
- ef20035648_8k.htm (8-K) — 28KB
- ef20035648_ex99-1.htm (EX-99.1) — 22KB
- 0001140361-24-040507.txt ( ) — 190KB
- roiv-20240909.xsd (EX-101.SCH) — 4KB
- roiv-20240909_lab.xml (EX-101.LAB) — 21KB
- roiv-20240909_pre.xml (EX-101.PRE) — 16KB
- ef20035648_8k_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclo sure. On September 9, 2024, Roivant Sciences Ltd. (the "Company") issued a press release providing an update on the Graves' Disease development program at Immunovant. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROIVANT SCIENCES LTD. Date: September 9, 2024 By: /s/ Matt Maisak Name: Matt Maisak Title: Authorized Signatory